Cannabis Ruderalis

thcscience_admin
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0
Line 39: Line 39:
}}
}}


'''MN 18''' is an [[indazole]]-based [[synthetic cannabinoid]] that is an [[agonist]] for the [[cannabinoid receptor]]s, with [[enzyme inhibitor|''K''<sub>i</sub>]] values of 45.72&nbsp;nM at [[cannabinoid receptor type 1|CB<sub>1</sub>]] and 11.098&nbsp;nM at [[cannabinoid receptor type 2|CB<sub>2</sub>]] and [[EC50|EC<sub>50</sub>]] values of 2.028&nbsp;nM at CB<sub>1</sub> and 1.233&nbsp;nM at CB<sub>2</sub>,<ref>{{cite journal|first1=Thomas F.|last1=Gamage|first2=Charlotte E.|last2=Farquhar|first3=Timothy W.|last3=Lefever|first4=Julie A.|last4=Marusich|title=Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA|url=http://jpet.aspetjournals.org/content/early/2018/03/16/jpet.117.246983|journal=Journal of Pharmacology and Experimental Therapeutics|volume=365|issue=1|date=April 2018|issn=0022-3565|pages=437–446|pmid=29549157|pmc=5932312|doi=10.1124/jpet.117.246983|first5=Richard C.|last5=Kevin|first6=Iain S.|last6=McGregor|first7=Jenny L.|last7=Wiley|first8=Brian F.|last8=Thomas}}</ref> and has been sold online as a [[designer drug]].<ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1276 | title=MN-18 | publisher=Southern Association of Forensic Scientists | accessdate=23 July 2015}}</ref><ref name="Uchiyama_2015">{{cite journal | title=A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products |author1=Nahoko Uchiyama |author2=Yoshihiko Shimokawa |author3=Ruri Kikura-Hanajiri |author4=Yosuke Demizu |author5=Yukihiro Goda |author6=Takashi Hakamatsuka | journal=Forensic Toxicology |date=February 2015 | doi=10.1007/s11419-015-0268-7 | pmid=26257833 | pmc=4525202 | volume=33 |issue = 2| pages=244–259}}</ref> It is the indazole core analogue of [[NNE1]]. Given the known metabolic liberation (and presence as an impurity) of [[amantadine]] in the related compound [[APINACA]], it is suspected that metabolic hydrolysis of the amide group of MN-18 may release [[1-naphthylamine]], a known [[carcinogen]]. MN-18 metabolism has been described in literature.<ref>{{cite journal | author1=Xingxing Diao | url=http://clinchem.aaccjnls.org/content/63/11/1753.long | title=Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18 | date=August 2017 | author2=Jeremy Carlier | author3=Mingshe Zhu | author4=Marilyn A. Huestis | journal=Clinical Chemistry | volume=63 | issue=11 | pages=1753–1763 | doi=10.1373/clinchem.2017.277152| pmid=28821542 }}</ref><ref>{{cite journal | author1=Richard C. Kevin | title=Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18 | date=August 2017 | author2=Timothy W. Lefever | author3=Rodney W. Snyder | author4=Purvi R. Patel | author5=Thomas F. Gamage | author6=Timothy R. Fennell | author7=Jenny L. Wiley | author8=Iain S. McGregor | author9=Brian F. Thomas | journal=Drug Testing and Analysis | volume=10 | issue=1 | pages=137–147 | doi=10.1002/dta.2262| pmid=28834241 | pmc=5785468 }}</ref>
'''MN 18''' is an [[indazole]]-based [[synthetic cannabinoid]] that is an [[agonist]] for the [[cannabinoid receptor]]s, with [[enzyme inhibitor|''K''<sub>i</sub>]] values of 45.72&nbsp;nM at [[cannabinoid receptor type 1|CB<sub>1</sub>]] and 11.098&nbsp;nM at [[cannabinoid receptor type 2|CB<sub>2</sub>]] and [[EC50|EC<sub>50</sub>]] values of 2.028&nbsp;nM at CB<sub>1</sub> and 1.233&nbsp;nM at CB<sub>2</sub>,<ref>{{cite journal|first1=Thomas F.|last1=Gamage|first2=Charlotte E.|last2=Farquhar|first3=Timothy W.|last3=Lefever|first4=Julie A.|last4=Marusich|title=Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA|url=http://jpet.aspetjournals.org/content/early/2018/03/16/jpet.117.246983|journal=Journal of Pharmacology and Experimental Therapeutics|volume=365|issue=1|date=April 2018|issn=0022-3565|pages=437–446|pmid=29549157|pmc=5932312|doi=10.1124/jpet.117.246983|first5=Richard C.|last5=Kevin|first6=Iain S.|last6=McGregor|first7=Jenny L.|last7=Wiley|first8=Brian F.|last8=Thomas}}</ref> and has been sold online as a [[designer drug]].<ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1276 | title=MN-18 | publisher=Southern Association of Forensic Scientists | accessdate=23 July 2015 | archive-url=https://web.archive.org/web/20150723222131/http://forendex.southernforensic.org/index.php/detail/index/1276 | archive-date=23 July 2015 | url-status=dead }}</ref><ref name="Uchiyama_2015">{{cite journal | title=A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products |author1=Nahoko Uchiyama |author2=Yoshihiko Shimokawa |author3=Ruri Kikura-Hanajiri |author4=Yosuke Demizu |author5=Yukihiro Goda |author6=Takashi Hakamatsuka | journal=Forensic Toxicology |date=February 2015 | doi=10.1007/s11419-015-0268-7 | pmid=26257833 | pmc=4525202 | volume=33 |issue = 2| pages=244–259}}</ref> It is the indazole core analogue of [[NNE1]]. Given the known metabolic liberation (and presence as an impurity) of [[amantadine]] in the related compound [[APINACA]], it is suspected that metabolic hydrolysis of the amide group of MN-18 may release [[1-naphthylamine]], a known [[carcinogen]]. MN-18 metabolism has been described in literature.<ref>{{cite journal | author1=Xingxing Diao | url=http://clinchem.aaccjnls.org/content/63/11/1753.long | title=Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18 | date=August 2017 | author2=Jeremy Carlier | author3=Mingshe Zhu | author4=Marilyn A. Huestis | journal=Clinical Chemistry | volume=63 | issue=11 | pages=1753–1763 | doi=10.1373/clinchem.2017.277152| pmid=28821542 }}</ref><ref>{{cite journal | author1=Richard C. Kevin | title=Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18 | date=August 2017 | author2=Timothy W. Lefever | author3=Rodney W. Snyder | author4=Purvi R. Patel | author5=Thomas F. Gamage | author6=Timothy R. Fennell | author7=Jenny L. Wiley | author8=Iain S. McGregor | author9=Brian F. Thomas | journal=Drug Testing and Analysis | volume=10 | issue=1 | pages=137–147 | doi=10.1002/dta.2262| pmid=28834241 | pmc=5785468 }}</ref>


==Legal status==
==Legal status==

Revision as of 01:35, 21 March 2020

MN-18
Legal status
Legal status
Identifiers
  • N-(naphthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H23N3O
Molar mass357.5 g/mol g·mol−1
3D model (JSmol)
  • CCCCCn1nc(c2c1cccc2)C(=O)Nc1cccc2c1cccc2
  • InChI=1S/C23H23N3O/c1-2-3-8-16-26-21-15-7-6-13-19(21)22(25-26)23(27)24-20-14-9-11-17-10-4-5-12-18(17)20/h4-7,9-15H,2-3,8,16H2,1H3,(H,24,27)
  • Key:UJKHLVOEXULDRU-UHFFFAOYSA-N

MN 18 is an indazole-based synthetic cannabinoid that is an agonist for the cannabinoid receptors, with Ki values of 45.72 nM at CB1 and 11.098 nM at CB2 and EC50 values of 2.028 nM at CB1 and 1.233 nM at CB2,[1] and has been sold online as a designer drug.[2][3] It is the indazole core analogue of NNE1. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of MN-18 may release 1-naphthylamine, a known carcinogen. MN-18 metabolism has been described in literature.[4][5]

Legal status

MN-18 is banned in Sweden.[when?][6] On 15 September 2014 the Turkey government banned the sale of MN-18.[7]

See also

References

  1. ^ Gamage, Thomas F.; Farquhar, Charlotte E.; Lefever, Timothy W.; Marusich, Julie A.; Kevin, Richard C.; McGregor, Iain S.; Wiley, Jenny L.; Thomas, Brian F. (April 2018). "Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA". Journal of Pharmacology and Experimental Therapeutics. 365 (1): 437–446. doi:10.1124/jpet.117.246983. ISSN 0022-3565. PMC 5932312. PMID 29549157.
  2. ^ "MN-18". Southern Association of Forensic Scientists. Archived from the original on 23 July 2015. Retrieved 23 July 2015.
  3. ^ Nahoko Uchiyama; Yoshihiko Shimokawa; Ruri Kikura-Hanajiri; Yosuke Demizu; Yukihiro Goda; Takashi Hakamatsuka (February 2015). "A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products". Forensic Toxicology. 33 (2): 244–259. doi:10.1007/s11419-015-0268-7. PMC 4525202. PMID 26257833.
  4. ^ Xingxing Diao; Jeremy Carlier; Mingshe Zhu; Marilyn A. Huestis (August 2017). "Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18". Clinical Chemistry. 63 (11): 1753–1763. doi:10.1373/clinchem.2017.277152. PMID 28821542.
  5. ^ Richard C. Kevin; Timothy W. Lefever; Rodney W. Snyder; Purvi R. Patel; Thomas F. Gamage; Timothy R. Fennell; Jenny L. Wiley; Iain S. McGregor; Brian F. Thomas (August 2017). "Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18". Drug Testing and Analysis. 10 (1): 137–147. doi:10.1002/dta.2262. PMC 5785468. PMID 28834241.
  6. ^ "Cannabinoider föreslås bli klassificerade som hälsofarlig vara". Folkhälsomyndigheten. 28 May 2014. Retrieved 23 July 2015.
  7. ^ "Turkish Drug Law List". Resmi Gazete. 15 Sep 2014.


source: https://en.wikipedia.org/w/index.php?title=MN-18&diff=prev&oldid=946574680

Leave a Reply